Trial Profile
Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2011 New trial record